ArticlePloS one2025
Exploring the antioxidant, antiglycation, and anti-inflammatory potential of Oroxylum indicum stem bark extracts.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Pretreatment Methods on Yield and Composition of Cold-Pressed Black Cumin (Foods (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative diseases occur when humans suffer from oxidative stress, glycation and prolonged inflammation. This study explores the antioxidant, antiglycation, and anti-inflammatory effects of extracts of Oroxylum indicum, a plant used in traditional medicines in Asia. Several extracts from its stem bark were obtained using hexane, ethyl acetate, and ethanol as extraction solvents. The extracts were analyzed using high-performance liquid chromatography (HPLC). The HPLC chromatograms showed that the different O. indicum extracts contained three major flavonoid compounds, namely baicalein, chrysin, and oroxylin A, as well as a phenolic compound, p-coumaric acid. The total phenolic content (TPC) and total flavonoid content (TFC) of the extracts were also determined. The ethyl acetate fractionated extract (EAFE) possessed the highest TPC (172 ± 8 mg/g extract) and TFC (147 ± 1 mg/g extract), several times higher than those of crude ethanol extract, ethanol fractionated extract (EFE) and hexane fractionated extract (HFE), respectively. According to the highest levels of TPC and TFC, EAFE showed the highest antioxidant activity with Trolox equivalent antioxidant activity of 9.7 ± 0.1 mM/mg and β-carotene bleaching inhibition of 79.5 ± 1.1%. The activities for the natural antioxidant quercetin were 3.1 ± 0.1 mM/mg and 88.7 ± 0.1%, respectively. EAFE showed the highest antiglycation activity using a bovine serum albumin-methylglyoxal assay with 89.1 ± 0.7% inhibition. These findings indicate that TPC and TFC are the determining factors for the antioxidant and antiglycation activities of the extracts. An in silico analysis suggested that the anti-inflammatory activity of the extracts is due to the inhibition of toll-like receptor 4 (TLR4) activity by direct binding of the bioactive compounds to the TLR4 protein. Our findings provide scientific support for the use of O. indicum in traditional medicine and demonstrate that EAFE has potential in mitigating oxidative stress, glycation, and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.